{"id":14725,"date":"2020-09-09T16:23:09","date_gmt":"2020-09-09T03:23:09","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=14725"},"modified":"2020-09-09T16:23:09","modified_gmt":"2020-09-09T03:23:09","slug":"eu-approves-imbruvica-plus-rituximab-in-first-line-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=14725","title":{"rendered":"EU approves Imbruvica plus rituximab in first-line CLL"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

EU approves Imbruvica plus rituximab in first-line CLL<\/h1>\n

<\/h2>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by The Pharma Letter<\/a><\/p>\n

Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have secured approval for a broader label for the BTK blocker Imbruvica (ibrutinib) in Europe.<\/p>\n

The decision extends the approved indication in chronic lymphocytic leukemia (CLL) to include first-line treatment in combination with the targeted biologic therapy rituximab, and comes months after the US regulator provided approval in the same indication.<\/p>\n

The decision is based on data from the Phase III E1912 study, which provides a favorable comparison with the established chemo-immunotherapy regimen fludarabine, cyclophosphamide and rituximab (FCR).<\/p>\n

Profitable partnership<\/h2>\n

First approved in 2013, Chicago-based AbbVie (NYSE: ABBV)\u00a0is jointly developing and commercializing Imbruvica with\u00a0J&J\u2019s pharma arm, Janssen.<\/p>\n

The firms are in an equal partnership in developing the drug, after AbbVie acquired the original development partner Pharmacyclics for $21 billion in 2015.<\/p>\n

The new approval in CLL represents the 11th approval overall for the product, and the sixth approval for Imbruvica in this cancer type.<\/p>\n

To continue reading this article on The Pharma Letter<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

There\u2019s a growing recognition that some of the CAR-T shortfalls in CLL are due to an impaired fitness of T cells in CLL patients.<\/p>\n","protected":false},"author":1,"featured_media":14726,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,23],"tags":[],"class_list":["post-14725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/09\/drug-for-cll.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14725"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14725\/revisions"}],"predecessor-version":[{"id":14727,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14725\/revisions\/14727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/14726"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}